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Summary
Reduced skeletal muscle performance contributes to exer-
cise intolerance in COPD and CHF patients, independent of
the severity of local organ dysfunction. Striking similarities are
observed in morphological and metabolic abnormalities in
peripheral skeletal muscle between these two disorders, point-
ing towards a decreased oxidative capacity. Both diseases also
share striking differences between peripheral muscles and the
diaphragm, which may therefore require a different therapeuti-
cal approach. The following possible underlying factors of mus-
cular alterations in COPD and CHF are discussed: hypoxia,
oxidative stress, disuse, weight loss and altered substrate
metabolism.
According to the definitions of the World Health Orga-
nization chronic diseases are not only characterized by
their primary impairments, but also by the resulting dis-
abilities or even handicaps [1]. Although the primary
impairments in chronic obstructive pulmonary disease
(COPD) and chronic heart faulure (CHF) clearly differ,
there is a striking resemblance in the systemic conse-
quences of these diseases and their effect on exercise
capacity and health status. Skeletal muscle function in
COPD and CHF has long been ignored as potential con-
tributor by focusing on the ventilatory and cardiac limita-
tions of exercise performance, respectively; but recent
research has shown that skeletal muscle function is im-
paired in moderate to severe COPD and CHF and also is
an important predictor of exercise limitation in both dis-
eases [2–4]. Muscle function depends, among others, on
perfusion, muscle mass, fibre composition and energy
metabolism [5]. It can be inferred that alterations in one
or more of these determinants play a role in reduced mus-
cle performance. Indeed, both in COPD and in CHF such
changes have been found and striking similarities be-
tween the two etiologically distinct disorders appear to be
present.
In this paper we will first present an overview of clini-
cal studies that have investigated impaired muscle func-
tion with special emphasis on muscle morphology and
energy metabolism in COPD and CHF. In the second part
of the paper, potential causes will be discussed including
hypoxia, oxidative stress, disuse, weight loss and altered
substrate metabolism.
Muscular Alterations in COPD and CHF
Muscle Performance
Muscle performance is largely characterized by
strength and endurance. Strength is defined as the capaci-
ty of the muscle to develop maximal force and endurance
as the capacity of the muscle to maintain a certain force in
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time, thus to resist fatigue. Loss of either one of these
aspects results in muscle weakness and, hence, in im-
paired muscle performance. Numerous studies have now
convincingly demonstrated that COPD and CHF are
commonly associated with muscle weakness [6–8]. Ham-
ilton et al. [3] found significantly reduced strengths of
both peripheral and respiratory muscles in patients suffer-
ing from respiratory failure, heart failure, or a combina-
tion of both as compared to healthy subjects. However,
strength and endurance seem not to be affected in the
same way in respiratory and peripheral muscles. This is
illustrated by the poor correlation between the strengths
of both muscle groups in both disorders [7, 8], compared
to a much stronger correlation in healthy subjects [9]. It
implies that the strength component of muscle weakness
is affected differently in peripheral and respiratory mus-
cles. In healthy subjects, as well as in patients, exercise
limiting symptoms are the sense of leg effort (exertional
discomfort) and/or breathlessness (exertional dyspnoea)
[10, 11]. Despite correlations between peripheral muscle
strength and performance in COPD and CHF [7, 10],
reduced endurance (Ffatigue) seems to be the dominat-
ing limiting factor in peripheral muscles in these patients,
since the sense of leg effort was one of the main reasons to
stop exercise [3, 11–13]. Recently, it has been shown that
early lactic acidosis occurs in COPD during exercise [14]
and that this is largely the result of lactate release from the
lower exercising limb [15]. In CHF reports lactate release
is thought to be a result of decreased blood flow to the
peripheral muscles. Muscle acidosis is a contributing fac-
tor to muscle fatigue [16].
Fatigue probably is not the main limiting factor in
respiratory muscle function. Morrison et al. [17] found
that COPD subjects have decreased respiratory muscle
strength and endurance. Fatigue of the respiratory muscle
may indeed occur during exercise, but it is not certain
whether this is an independent determinant of exercise
capacity [12, 18, 19]. In addition, it is unlikely that the
respiratory muscles from exercising COPD patients con-
tribute to the lactate response mentioned earlier [20]. It
also should be emphasized that the respiratory muscles
must operate against the mechanical airway impedances
in this specific disorder [21], for which the force compo-
nent of respiratory muscle function is most likely of great
importance. For CHF it was found that respiratory mus-
cle strength and not respiratory muscle fatigability corre-
lated with the degree of dyspnoea [22]. It thus seems that
strength is the limiting aspect of muscle performance in
the respiratory muscle, whereas endurance limitation
dominates in peripheral muscles. However, more detailed
studies are required to clarify the individual roles of
strength and endurance limitation in peripheral and respi-
ratory muscles in COPD and CHF.
Muscle Morphology
In both CHF [10, 23] and COPD [2, 24–27] marked
loss of muscle mass or decline in cross-sectional area is
observed. This muscle wasting plays an important role in
the loss of exercise tolerance in these patients. Morpholog-
ical alterations may also be related to muscle function
impairment, although direct relationship with exercise
performance have not (yet) been shown. Some histologi-
cal information is available on abnormalities in skeletal
muscle in CHF but hardly any on COPD. Recently,
reduced fibre cross-sectional area has been demonstrated
in the vastus lateralis of COPD [28] and CHF [29]. Gertz
et al. [30] found no sings of increased fibrosis or other
alterations in intercostal muscles from patients with respi-
ratory failure, whereas endomyosal fibrosis has been
found in skeletal muscle of a limited number of CHF
patients [31]. Increased acid phosphatase activity, a lyso-
somal enzyme contributing to protein degradation, has
been found in the quadriceps of some patients with CHF
[32] or respiratory failure [27]. Increased lipid deposits
have been found in the quadriceps, biceps and deltoids of
some patients with CHF [27, 32]. Very contradicting
results have been obtained with respect to capillary densi-
ty in peripheral skeletal muscle in CHF. A normal capil-
lary density has been found [27], which is in confirmation
with other studies where both a reduced capillary/fibre
ratio and atrophy resulted in an unchanged capillary den-
sity [32]. An unaltered capillary/fibre ratio has also been
reported; however, capillary density increased due to fibre
atrophy [34]. In contrast, reduced capillary density in
combination with a reduced capillary/fibre ratio has been
shown in CHF patients [35] and even in heart transplan-
tation recipients [36]. Thus, there is an overall tendency
for a reduced capillary/fibre ratio, but depending on the
degree of atrophy the capillary density may even be
increased. This has recently been confirmed for COPD
[25]. In a few studies morphometry of mitochondria has
been performed using electron microscopy, showing that
mitochondrial volume densities in skeletal muscle are
lower in CHF patients compared to control subjects [35,
37], which was still the case 10 months after heart trans-
plantation [36]. Histochemical alterations reflecting mito-
chondrial abnormalities have also been reported in biceps
muscle biopsies of COPD patients [27]. These results sug-




Muscle Fibre Type Distribution
The most remarkable muscle alteration in COPD and
CHF is a relative shift in fibre composition which seems
to occur in opposite direction in peripheral and respirato-
ry muscle. Fibre typing is mainly performed histochemi-
cally, based on the differences in myosin ATPase activi-
ties, or immunocytochemically [38]. Adult mammalian
skeletal muscle contains four myosin heavy chain
(MyHC) isoforms, namely type I, IIa, IIb and IIx [39]. In
most older studies fibre typing is limited to determining
fibre types I, IIa and IIb. Furthermore, human fibres for-
merly identified as being IIb with myosin ATPase stain-
ing are probably IIx fibres [40]. Therefore the notation
IIb/x will be used in the subsequent text. Fibre type I has a
slow-twitch and develops a relative small tension, but
since it depends mainly on aerobic metabolism it is
fatigue resistant. In contrast, fibre type IIb/x has a fast-
twitch and develops large tensions, but it is susceptible for
fatigue, since in type IIb/x fibres energy conversion is
based on anaerobic, glycolytic metabolism. Fibre type II
has intermediate properties in that it also has a fast
twitch, develops a moderate tension, is relatively resistant
to fatigue and is apt to work under both aerobic and
anaerobic conditions [5, 38]. A decrease of the percentage
of type I fibres and a corresponding increase in type II
(mainly type IIb/x) fibres compared to normal subjects
has been reported for COPD [25, 41, 42] and for CHF
[32–35, 43] in limb muscles. In addition, recently we
demonstrated increased proportions of I/IIa and IIa/IIx
hybrid fibres in COPD [44]. These fibres may represent
transformation intermediates in the I→IIx shift. In con-
trast to peripheral muscles, a shift from type IIb/x to type I
fibres has been reported in the diaphragm in both COPD
and CHF patients. Despite some variation in the results
obtained till now, there is most likely a I→IIb/x shift in
peripheral muscles and a IIb/x→I shift in the respiratory
muscle. It is feasible that these shifts have functional con-
sequences in the affected muscles, since the distinct fibre
types have different contractile properties with respect to
twitch and fatigue resistance. Therefore, in COPD and
CHF, a I→IIb/x shift accompanied by more glycolytic and
less oxidative capacity in peripheral muscles implies loss
of fatigue resistance. This change might contribute to the
observed loss of exercise tolerance, since peripheral mus-
cle fatigue is the main limiting factor in these patients.
This is confirmed by a study in which a faster twitch
response in combination with less resistance to fatigue
was observed in leg muscles of CHF patients [45]. Accord-
ingly, a IIb/x→I shift towards more oxidative metabolism
in the respiratory muscle implies a shift towards a more
fatique-resistant, but less strength adapted muscle. This
too is in line with our notion that strength and not fatigue
seems to be the main limiting factor for respiratory mus-
cle function.
Muscle Energy Metabolism
Considerable amounts of data are available on skeletal
muscle metabolism in CHF and COPD, partly because of
the applicability of 31P-nuclear magnetic resonance (31P-
NMR) which has enabled a direct and non-invasive
assessment of tissue levels of high-energy phosphates and
pH. High levels of adenosine triphosphate (ATP), crea-
tine phosphate (CrP) and nicotinamide adenine dinucleo-
tide in the reduced form (NADH) reflect a high energy
state, whereas elevated levels of adenosine diphosphate
(ADP), adenosine monophosphate (AMP), inorganic
phosphate (Pi) and oxidized nicotinamide adenine dinu-
cleotide (NAD+) commonly reflect a low energy state.
Lactate and glycogen levels are often measured, but it
must be noted that low levels may reflect either increased
clearance or reduced formation and vice versa for high
levels. Although activities of enzymes involved in muscle
energy metabolism do not reflect the physiological situa-
tion since only maximal activities are obtained under the
optimal circumstances of in vitro measurements, they do
provide an indication for adaptations in expressions of
proteins involved in metabolic pathways. Typical oxida-
tive enzymes are citrate synthase (CS), succinate dehydro-
genase (SDH) and ß-hydroxyacyl-CoA dehydrogenase
(HAD). Typical glycolytic enzymes are hexokinase (HK),
phosphofructokinase (PFK) and lactate dehydrogenase
(LDH), the latter catalysing the last step of anaerobic gly-
colysis. Measurements of substrate and cofactor levels in
peripheral skeletal muscle of COPD and CHF patients
indicate impaired energy metabolism (see table 3). Most
striking are the observed reduced levels of the high-energy
phosphates in rest. Pouw et al. [46] observed higher Pi/
Crp and ADP/ATP ratios associated with slightly, but sta-
tistically significantly elevated inosine monophosphate
(IMP) levels. The latter may be due to increased degrada-
tion of accumulating AMP by deamination, which proba-
bly reflects reduced aerobic capacity [47]. The situation
becomes even worse during exercise: greater increase of
the Pi/CrP ratio and a faster drop in pH were found in the
calf muscle of COPD patients [48, 49] and of CHF
patients [34, 50, 51] performing exercise. Similar results
have been obtained for the forearm muscle [51, 52] (ta-
ble 1). In addition, a slower recovery of CrP was observed
COPD
COPD
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Table 1. Changes in muscle energy
metabolism during exercise Disorder Ref. Muscle Variables of NMR spectroscopy
PCr Pi/PCr PCr/(PCr+Pi) ATP relATP pH
54 calf ↓ ↓
53 calf ↑ = ↓
55 calf ↑ ↓ ↓
56 quadriceps = =
57 forearm ↓ NS =
58 forearm ↑ ↓ ↑ ↓
CHF 60 calf* = = = = = =
60 calf** ↑ = ↑ ↓
59 calf = ↓
34 calf ↓
61 calf ↓
57 forearm ↓ NS =
Pi = Inorganic phosphate; PCr = phosphocreatine; ATP = adenosime triphosphate;
relATP = ATP corrected for Pi/PCr; ↑ significantly increased compared to controls; ↓ signifi-
cantly decreased compared to controls; = means in patients not significantly different from
controls; * compared to sedentary controls; ** compared to trained controls.
Table 2. Muscle energy metabolism in the recovery phase after exercise
Disorder Ref. Muscle Variables of NMR spectroscopy




58 forearm ↑ ↑
57 forearm ↑ ↓ ↑
CHF 60 calf* =
60 calf** =
61 calf ↑
57 forearm ↑ ↓ ↑ ↓ NS
Pi = Inorganic phosphate; PCr = phosphocreatine; RT1/2 = recovery halftime; ↑ significantly increased compared
to controls; ↓ significantly decreased compared to controls; = means in patients not significantly different from
controls; * compared to sedentary controls; ** compared to trained controls.
after exercise [34, 49–52]. COPD patients also show a
prolonged half-time (RT½) for pH [53–55, 57, 58] (ta-
ble 2). These results suggest that rephosphorylation of
high-energy phosphates is less efficient in these patients
both during and after muscular exercise. In CHF patients,
Chati et al. [60] compared NMR spectra of calf muscles
during exercise with sedentary and trained controls. They
found no difference between patients and sedentary con-
trols and concluded deconditioning being an important
factor for the abnormalities. In addition, glycogen con-
tents in patients tend to be lower, whereas lactate levels
are higher (table 3). It thus seems that anaerobic energy
metabolism is enhanced and since this process yields far
less ATP compared to complete oxidative degradation of
22 Gosker/Uszko-Lencer/Wouters/
van der Vusse/Schols
Table 3. Muscle metabolite concentrations in COPD and CHF
Metabolite Muscle Disorder Direction References
CrP QF COPD ↓ 30, 124, 125, 126*
QF CHF ↓ 127, 128*
ATP QF COPD ↓ 30, 124, 125, 126*
QF CHF ↓ 127, 128*
IMP TA COPD ↑ 46
Glycogen QF CHF ↓ 32, 127, 128
QF COPD ↓ 124, 125*
Lactate QF COPD ↑ 30, 126
QF CHF ↑ 129
Pyruvate QF CHF ↑ 32
QF COPD ↑ 14
ATP = Adenosine triphosphate; CrP = creatine phosphate; IMP =
inosine monophosphate; QF = quadriceps femoris; TA = tibialis
anterior; * nearly reached significance.
Table 4. Muscle enzyme activities
Enzyme Muscle Disorder Direction References
CS QF COPD ↓ 130, 131
QF CHF ↓ 32, 34, 129, 132
DIA CHF ↑ 133
HAD QF COPD ↓ 130, 131
QF CHF ↓ 32, 34, 129, 132
DIA CHF ↑ 133
SDH QF COPD ↓ 131
QF CHF ↓ 32, 132
LDH QF COPD ↑ 131
QF CHF ↑ 129*
DIA CHF ↓ 133
DIA COPD ↓ 134
HK QF CHF ↓ 132
DIA COPD ↓ 134
PFK QF COPD ↑ 131
CS = Citrate synthase; HAD = ß-hydroxyacyl-CoA dehydroge-
nase; SDH = succinate dehydrogenase; HK = hexokinase; PFK =
phosphofructokinase; LDH = lactate dehydrogenase; QF = quadri-
ceps femoris; DIA = diaphragm.
glucose this could explain the reduced high-energy phos-
phate levels.
Analysis of enzyme activities too suggest an overall
increase of glycolytic and an overall decrease of oxidative
activities in peripheral muscles of both COPD and CHF
patients (table 4). Since these enzyme activities depend
largely on the fibre type [62], it is likely that this shift in
activities is related to the shift in fibre distribution men-
tioned above. Whether enzyme activities adapt to the
fibre type redistribution or the other way around remains
unclear. Due to technical difficulties with 31P-NMR and
muscle biopsies of the diaphragm and accessory respirato-
ry muscles, very little is known about energy metabolism
in these muscles. However, the observed alterations for
enzyme activities (table 4) are in confirmation with the
morphological data, in that oxidative enzyme activities
are reduced and glycolytic enzyme activities are in-
creased. As in peripheral muscles, this shift probably
results from the shift in fibre type distribution.
Possible Underlying Factors
Hypoxia
In COPD and CHF oxygen delivery to peripheral and
respiratory muscles may be insufficient, caused by either
hypoxemia and/or reduced blood supply. In both cases
muscle tissue may become hypoxic and this could lead to
the adaptive changes in skeletal muscle as those described
above. In this respect relevant information is now avail-
able from mountaineering expeditions (lasting at least 6
weeks above 5,000 m), since oxygen is limited at this alti-
tude. Under these conditions reductions in mitochondrial
volume densities, in oxidative enzyme activities and in
cross sectional areas of muscle fibers were found in the
quadriceps [63, 64]. But such expeditions are accompa-
nied by strenuous physical activity, which also causes
muscular adaptations other than those caused by hypoxia.
In fact, the effect of training in combination with hypoxia
may even cause a shift towards more oxidative metabo-
lism [65].
More information about the effect of hypoxia on mus-
cle has been obtained from animal studies. Several of
these studies have shown that hypoxia can indeed lead to
the muscular alterations as described for limb muscles in
COPD and CHF: (1) Reduced fibre diameters in combi-
nation with unaffected numbers of capillaries, resulting in
increased capillary densities, have been reported in rats
exposed to hypoxia [66, 67]. (2) Some studies revealed
that hypoxia depresses protein synthesis [68, 69], includ-
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ing in muscle tissue [68]. Chronic hypoxia inhibits the
normal conversion of type IIa to type I fibres in growing
rats, resulting in a predominating proportion of type IIa
fibres compared to control rats [70]. So hypoxia does not
directly cause a type I → II fibre shift, but causes an
abnormal fibre type distribution from alterations in mus-
cular development. It is feasible that in COPD and CHF a
similar mechanism underlies the abnormal fibre type dis-
tribution in the regeneration of damaged muscle or the
adaptation of muscles to consequences of the disease.
(3) There is evidence that hypoxia causes a shift towards
glycolytic metabolism, resulting in an increased lactate-
to-pyruvate ratio [71, 72] and reduced malate dehydroge-
nase, a citric acid enzyme [73]. (4) Hypoxia causes stimu-
lation of glucose transport [74] and increased levels of
membrane-associated glucose transporters (GLUT1 and
GLUT4) in rat muscle [75].
It should be noted, however, that in COPD and CHF
this reduction of oxidative capacity does not occur in the
diaphragm. It is feasible that hypoxia causes an endur-
ance training effect in the diaphragm due to increased
ventilation, which overrides its direct effect ultimately
resulting in a shift towards more aerobic metabolism.
Oxidative Stress
Oxidative stress may be another factor contributing
via reactive oxygen species to muscle damage. In both
COPD and CHF increased plasma levels of lipid peroxi-
dation products have been found [76, 77]. Sources of free
oxygen radicals are: (1) Mitochondria, since 2–5% of the
total oxygen consumed is not fully reduced in the electron
transport chain and may leak away as superoxide radicals
[78, 79]. (2) Immune cells activated during inflammation
[80]. Monocytes and macrophages produce cytokine tu-
mor necrosis factor-· (TNF·) which may in turn induce
oxidative stress in myocytes [81]. Elevated TNF· blood
levels have indeed been found in both COPD [82, 83] and
CHF [84, 85], in particular in those patients characterized
by weight loss and/or muscle wasting. (3) Xanthine oxi-
dase, in case of a low energy state, is involved in the degra-
dation of AMP [79]. The above-mentioned elevated IMP
levels in COPD [46] indeed suggest enhanced AMP
breakdown. Susceptibility to these free radicals largely
depends on the antioxidant status of tissue [79]. The main
antioxidant scavengers and enzymes are, amongst others,
reduced glutathione, vitamin E (in cell membranes), su-
peroxide dismutase (SOD), glutathione peroxidase and
catalase [79, 86]. Long-term training stimulates the de-
fense system against oxygen free radicals [78, 79, 86] and
the disuse of muscles thus may lack this antioxidant stim-
ulating trigger resulting in a reduced antioxidant status.
Chronic hypoxia probably acts in the same way, since lim-
itations of oxygen supply are indeed found to be associat-
ed with reductions in SOD activity in mammalian tissues
like brain, lungs and heart, although this change was not
found in skeletal muscle tissue [87, 88]. In addition, in
myocytes (obtained from chronic hypoxic human myo-
cardium) cultured at low oxygen tension, antioxidant
enzyme activities were lower than in myocytes cultured at
a higher oxygen tension, illustrating the direct modulatory
effect of oxygen [89]. In vivo and in vitro hypoxia-reoxy-
genation studies revealed that oxygen oversupply follow-
ing a period of oxygen shortage may give rise to free radi-
cal formation in myocytes [87, 90]. Accordingly, in
COPD and CHF chronic hypoxia may result in a reduced
antioxidant status and occasional bouts of exercise may
cause a boost of free radicals exceeding the capacity of the
defence system [78]. It is also feasible that the reduced
oxidative capacity in the patients itself leads to enhanced
oxidative stress, since the sudden oversupply of oxygen
during exercise is inefficiently metabolised.
Reactive oxygen species are well capable of damaging
lipids and proteins [78, 79, 86, 91]. Radicals that react
with fatty acyl moieties in membrane phospholipids cause
a chain reaction of peroxidations increasing the mem-
brane permeability [91]. Maintenance of membrane in-
tegrity is crucial for: (1) Adequate functioning of the respi-
ratory chain, since the driving force for oxidative ATP
synthesis is the electrochemical proton gradient over the
inner membrane of the mitochondrion, which is gener-
ated during the electron transfer from NADH to oxygen
[92]. (2) To prevent intracellular calcium overload,
caused by damaged sarcoplasmatic reticulum membrane,
in combination with impaired activity of calcium
ATPases, which accompanies oxidative stress in animal
myocytes [78, 87, 90, 93], and may further uncouple res-
piration from ATP production through extensive depolar-
isation of the inner membrane [94].
Protein oxidation by oxygen free radicals leads to for-
mation of carbonyl groups on amino acid residues, which
may modify the structure and/or chemical properties of
the proteins affected [95]. These alterations may cause
decline in function or even complete protein unfolding.
The latter gives rise to enhanced susceptibility to protein-
ases. These modified proteins may also be recognized as
foreign substances and, hence, be attacked by the immune
system. Whether radical induced protein damage plays a
role in the abnormalities in muscles of COPD and CHF
patients is unclear. It has been shown in animal studies
that in vivo induced oxidative stress caused myofibrillar
24 Gosker/Uszko-Lencer/Wouters/
van der Vusse/Schols
muscle protein modification and that these proteins were
rapidly degraded by proteases [96]. Thus theoretically,
muscle atrophy can be enhanced by radical induced pro-
tein damage. Indeed, it has been shown that a calcium
overload is involved in muscle atrophy [97] and that vita-
min E deficiency facilitates muscle wasting and necrosis
[98], both probably mediated by oxidative damage to pro-
teins. Also, in human skeletal muscle it has been shown
that mitochondria and mitochondrial proteins were more
susceptible to oxidative damage compared to other sub-
cellular components [99], which suggests that protein
damage may cause impaired oxidative metabolism.
As opposed to necrosis, which is the result of exoge-
nous damage as described above, apoptosis of muscle cells
is an active process of cell death, which recently also has
been associated with oxidative stress [100]. In this study
the exposure of rat myoblasts to nitric oxide or hydrogen
peroxidase led to apoptotic cell death. Since these chemi-
cal stimuli are also released by immune cells, it cannot be
excluded that apoptosis underlies muscle wasting during
inflammation.
Disuse
Disuse (low level of physical exercise because of their
disease) of skeletal muscle is also a factor that most likely
contributes to the observed muscle alterations in COPD
and CHF. This results in: (1) Muscle weakness, due to
reduced motor neuron activity and muscle wasting [38,
101]. (2) Relative reduction in the percentage of type I
fibres and an increase in the percentage of type IIb/x
fibres [38, 102]. (3) A decline in activity of enzymes
involved in oxidative energy conversion, which occurs
both in type I and type II fibres [102], suggesting that it
can occur even without any change in fibre composition.
(4) A negative effect on the antioxidant status enhances
the risk of oxidative damage. As mentioned above, the
diaphragm is probably not disused and a kind of endur-
ance training effect may even occur. This may not only be
true for COPD, but for CHF as well, since especially in
severe CHF dyspnoea and elevated ventilation occur
already at rest [13, 103].
Weight Loss and Altered Substrate Metabolism
Weight loss commonly occurs in COPD [104, 105] and
in CHF [23, 106] and is an independent determinant of
mortality [107, 108]. In both disorders in particular loss of
FFM is an important determinant for exercise capacity [2,
24, 109]. Determination of body composition, and not
only weight, with respect to nutritional depletion is very
important since at least in COPD different patterns of
weight loss can be distinguished: predominant loss of fat
mass, predominant loss of fat-free mass or a combination
of both. Predominant loss of fat mass involves an im-
paired balance between energy requirement and energy
intake. Although limited information is available in CHF
patients, a negative energy balance commonly occurs in
COPD as a result of either a decreased dietary intake, ele-
vated energy requirements or a combination of both.
Total daily energy metabolism (TDE) can be divided in 3
components: resting energy expenditure (REE), measured
under fasting conditions in the early morning, diet in-
duced thermogenesis (DIT) and physical activity induced
(PAI) thermogenesis. REE comprises the major part of
TDE, DIT on average only 10–15% and PAI can be highly
variable. While in many chronic wasting diseases, REE is
increased, probably related to an enhanced systemic in-
flammation, TDE is not different from healthy control
subjects due to a compensatory decrease in daily activi-
ties. In contrast, TDE in COPD was found to be increased
as a result of an increased PAI [110]. It is yet unclear to
what extent an increased PAI is related to a decreased
mechanical or a decreased metabolic efficiency and what
the contributing role is of peripheral skeletal muscles ver-
sus the diaphragm.
In a situation of semistarvation, either primarily due to
increased energy requirements or due to decreased dietary
intake, loss of both fat mass and fat-free mass occurs, but
the loss of fat-free mass is relatively preserved. Therefore,
intrinsic muscle abnormalities besides loss of muscle
mass must account for impaired muscle performance.
Studies on muscle function and histology in anorexia ner-
vosa patients provide strong data on the effect of under-
nutrition per se on muscles. Muscle performance is mark-
edly impaired in these patients [111–113] and is associat-
ed with weight loss, loss of muscle mass and fibre atrophy
(particularly of type II fibres) [114, 115]. We recently
demonstrated selective fibre type IIx atrophy in COPD
patients associated with a reduced fat-free mass, suggest-
ing a role for undernutrition in this disease too [44]. Data
from animal studies confirm these effects of undernutri-
tion. Decreased activities of enzymes involved in glycolyt-
ic and mitochondrial pathways have been reported from
muscle biopsies of patients with anorexia nervosa [99,
111], with glycolytic capacity being affected the most
[111]. The contribution of nutritional depletion to a shift
from oxidative to glycolytic metabolism in COPD and
CHF patients needs further investigation.
Disproportionate loss of fat-free mass often referred as
cachexia, involves an impaired balance between protein
anabolism and catabolism. Protein depletion itself may
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impair skeletal muscle performance as reflected by re-
duced maximum voluntary handgrip strength, reduced
respiratory muscle strength and an increased fatigability
of in vivo electrically stimulated adductor pollicis muscle
[116]. Predominant loss of fat-free mass with relative
preservation of fat mass also points towards alterations in
substrate metabolism. Partly independent of pulmonary
or cardiac cachexia, other disease characteristics like hyp-
oxia or hypercapnia may alter substrate metabolism.
Insulin has a central role in substrate metabolism. Hyper-
insulinemia has been described in COPD and insulin
resistance commonly occurs in CHF. While nearly no
data are available regarding carbohydrate and fat metabo-
lism in fasting, fed or stressed states, protein metabolism
has been subject of recent investigations in COPD. In
nondepleted COPD patients, an increased whole-body
protein turnover was observed at rest and specifically in
emphysema a suppressed whole body protein turnover
was observed during and immediately after exercise [118,
119]. Whole-body protein turnover, however, does not
necessarily reflect muscle protein turnover. A study in
underweight patients with emphysema reported a re-
duced muscle protein synthesis [117], while protein deg-
radation was not increased [119, 120]. It is feasible that
amino acids are required in other processes than muscular
protein synthesis, such as gluconeogenesis. Besides, recent
data also showed intrinsic alterations in the amino acid
profile of peripheral skeletal muscles. Most consistent
results were found with respect to the amino acid gluta-
mate (GLU). Intracellular GLU has various important
functions, as it plays an important role in preserving high-
energy phosphates in muscle through different metabolic
mechanisms. GLU concentration is high in the free ami-
no acid pool of human skeletal muscle. Intracellular GLU
is known as an important precursor for the antioxidant
glutathione (GSH) and glutamine synthesis in the muscle.
Muscle GLU is indeed highly associated with muscle
GSH, and patients with emphysema suffer from de-
creased muscular GLU and GSH levels [122]. Studies
have shown that in healthy human muscle, the GLU pool
functions to generate tricarboxylic acid (TCA) interme-
diates during the first minutes of exercise, which is
achieved via the alanine aminotransferase reaction (pyru-
vate + GLU → alanine + ·-ketoglutarate) at the cost of
GLU. Moreover, this reaction can shunt the pyruvate
accumulated during exercise towards alanine instead of
lactate, suggesting a possible role of the intracellular GLU
level in the lactate response to exercise. In line with this
hypothesis early lactic acidosis during exercise in patients
with COPD was indeed associated with a reduction in
muscle GLU [14]. Not only at rest, but also during 20 min
of submaximal constant cycle exercise a different re-
sponse in amino acid status was found in skeletal muscle
and plasma of COPD patients as compared with healthy
age-matched controls [123]. A significant reduction of
most muscle amino acids was present postexercise, where-
as several plasma amino acids were increased, suggesting
an enhanced amino acid release from muscle in COPD
during exercise. The increase in plasma alanine and gluta-
mine was even higher postexercise, suggesting enhanced
nitrogen efflux. Although investigation of substrate me-
tabolism in COPD and CHF is still in its infancy, the
available studies clearly point towards therapeutic per-
spective, not only in cachectic patients, but also as ana-
bolic stimulus to enhance muscle and exercise perfor-
mance. In frail elderly it has indeed been observed that
oral amino acid intake stimulates the transport of amino
acids into muscle, and that there is a direct link between
amino acid transport and protein synthesis when ingested
before exercise or some time after exercise.
Conclusions
This review underscores that reduced skeletal muscle
performance markedly contributes to exercise intolerance
in COPD and CHF patients. Morphologic and metabolic
abnormalities occur in the skeletal muscles of these pa-
tients which, in both disorders, probably are determined
by the same set of contributing factors. Both diseases also
share striking differences between peripheral muscles and
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